Does Medicare Cover GLP-1s for Weight Loss in 2026? The New Bridge Program Explained

Yes — but this is brand new. Starting July 1, 2026, Medicare covers GLP-1 weight-loss drugs for the first time through a pilot called the GLP-1 Bridge program. For years, federal law blocked Medicare Part D from paying for any medication used purely for weight loss, a rule dating back to the 2003 Medicare Modernization Act. That barrier is what kept Wegovy and Zepbound off Medicare formularies even as they transformed obesity treatment.

The Bridge program is a workaround run through the Center for Medicare & Medicaid Innovation. Instead of permanently rewriting the law, it creates a time-limited pilot that lets participating Part D plans cover specific weight-loss GLP-1s at a predictable price. It launches July 1, 2026 and is scheduled to run through December 31, 2027, after which a broader effort called the BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) is expected to take over.

If you have struggled to afford these drugs out of pocket, this is a meaningful shift. To understand how big a deal the pricing is, it helps to compare it with [other ways to get GLP-1s cheaper](/blog/how-to-get-glp1-cheaper-savings-cards-telehealth-2026), where monthly costs without coverage often run well over $500.

The Bridge program covers the weight-loss versions of GLP-1 medications, not the diabetes versions. Specifically, eligible members can get:

• •Wegovy (semaglutide) — both the injection and the newer oral tablet
• •Zepbound KwikPen (tirzepatide) — the multi-dose pen format
• •Foundayo (tablet) — an oral option included in the pilot

There is an important exclusion: the program does not cover single-dose Zepbound vials or single-dose pens — only the KwikPen multi-dose format. If you currently use vials, you may need to switch formats to use the benefit.

Notice what is *not* on the list: Ozempic and Mounjaro. These contain the same active ingredients as Wegovy and Zepbound (semaglutide and tirzepatide), but they are FDA-approved for type 2 diabetes, not weight loss. Medicare Part D already covers Ozempic and Mounjaro for people with diabetes, and the Bridge program does not change that. It only adds the weight-loss branded versions. If you are weighing formats, our guide to [oral versus injectable GLP-1s](/blog/oral-vs-injectable-glp1-which-is-right-for-you-2026) explains the trade-offs now that tablets are part of the mix.

Eligibility centers on being enrolled in a participating Medicare Part D plan and meeting clinical criteria for obesity treatment. Because this is a pilot, not every Part D plan participates, and the exact medical requirements are set through the plan and your prescriber. In general, you can expect criteria similar to the FDA labels for these drugs: a body mass index (BMI) of 30 or higher, or a BMI of 27 or higher with a weight-related condition such as high blood pressure, high cholesterol, or sleep apnea.

A few practical points. First, you need a prescription from your provider documenting the weight-loss indication — the coverage follows a clinical decision, not a self-request. Second, because participation varies by plan, you should call your Part D plan directly or check its 2026 formulary to confirm it joined the Bridge pilot and lists the specific drug you want. Third, enrollment timing matters: if your current plan does not participate, you may need to wait for the annual Medicare open enrollment window (October 15 to December 7) to switch.

The program is designed to lower the single biggest barrier — cost — but it does not remove the clinical gatekeeping. You still need a prescriber who agrees a GLP-1 is appropriate for you.

The headline price is excellent: a flat $50 copay per 30-day supply, and crucially, that copay does not increase as your dose goes up. With many medications, titrating to a higher maintenance dose means a higher price. The Bridge program holds the line at $50 regardless of strength, which makes budgeting far easier.

But there are two real catches you need to understand. First, the $50 copay does not count toward your Part D deductible. Second, and more significant, it does not count toward the $2,100 annual out-of-pocket cap on prescription drug costs that protects Medicare beneficiaries in 2026. In other words, money you spend on your GLP-1 through this pilot is essentially 'outside' the normal Part D cost-sharing structure — it will not help you reach the cap faster on your other medications.

For most people, $50 a month — about $600 a year — is still a dramatic improvement over paying $500 to $1,000 a month out of pocket. Just go in clear-eyed that this is a separate bucket of spending. If you also carry commercial questions about coverage, our overview of [whether insurance covers GLP-1s for weight loss](/blog/does-insurance-cover-glp1-for-weight-loss-2026) covers the non-Medicare side.

The Bridge program is explicitly a temporary pilot, scheduled to run through December 31, 2027. After that, Medicare plans to transition to the BALANCE Model — Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth — a broader, longer-term framework for covering obesity care that pairs medication with lifestyle support like nutrition and activity coaching.

Why structure it this way? Pilots let Medicare test cost, uptake, and outcomes before committing to permanent, nationwide coverage of drugs that could cost the program tens of billions of dollars a year. The Bridge buys time to gather data while still giving beneficiaries access now.

For you, the practical implication is to not assume your $50 copay is permanent. Coverage rules, participating plans, and covered drugs could all change when BALANCE begins. Stay in touch with your Part D plan during each fall open enrollment, keep your prescription current, and watch for official Medicare announcements about the transition. If you are also navigating midlife weight changes, combining medication coverage with the right lifestyle foundation matters even more — something Lea can help you map out.

Take three concrete steps. First, call the member services number on the back of your Part D card and ask directly: 'Does my plan participate in the Medicare GLP-1 Bridge program, and is [Wegovy / Zepbound KwikPen / Foundayo] on the 2026 formulary?' Get the answer in writing or note the reference number for the call.

Second, check your plan's 2026 formulary online, searching for the specific drug and format. Remember that single-dose Zepbound vials are excluded, so confirm the KwikPen is listed if tirzepatide is your goal.

Third, talk to your prescriber about documentation. The coverage requires a clinical weight-loss indication, so your provider needs to record your BMI and any weight-related conditions. If your current plan does not participate, mark your calendar for Medicare open enrollment, October 15 to December 7, when you can switch to a plan that does.

This is a lot of moving parts, and the rules are new. If you want help turning this into a simple checklist for your situation, Lea can walk through it with you step by step.